Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anaptysbio Inc (NQ: ANAB )

23.12 +0.50 (+2.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 438,394
Open 22.62
Bid (Size) 18.88 (1)
Ask (Size) 40.00 (1)
Prev. Close 22.62
Today's Range 22.18 - 23.33
52wk Range 18.20 - 37.89
Shares Outstanding 27,433,359
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga

Performance

YTD
-35.67%
-35.67%
1 Month
+21.94%
+21.94%
3 Month
-6.59%
-6.59%
6 Month
-36.66%
-36.66%
1 Year
-12.56%
-12.56%

More News

Read More
Short Volatility Alert: AnaptysBio, Inc.
Via Benzinga
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
AnaptysBio's Return On Capital Employed Insights
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Via Benzinga
Recap: AnaptysBio Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2022
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Via Benzinga
AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
AnaptysBio's Return On Capital Employed Insights
Via Benzinga
Hoth Therapeutics Reports Being Set To Begin Phase 2 Study On First-Of-Its-Kind Skin Toxicity Ointment For Cancer Patients
Via Benzinga
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
Via Benzinga
AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis
Via Benzinga
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication
Via Benzinga
Exposures Product Safety
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics, And More
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021
Via Benzinga
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More
Via Benzinga
Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More
Via Talk Markets
Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.